血管假体市场按产品类型、血管直径、适应症、最终用户和分销管道划分 - 全球预测 2025-2032

预计到 2032 年血管移植市场规模将成长至 41.3 亿美元，复合年增长率为 7.58%。

主要市场统计数据
基准年2024年	23亿美元
预计2025年	24.7亿美元
预测年份：2032年	41.3亿美元
复合年增长率（%）	7.58%

一个简洁的技术框架，涵盖临床、技术和商业性要求，将塑造下一个时代的血管移植利用和策略

血管移植领域正处于关键的曲折点源于临床需求、材料创新和不断发展的医疗服务模式的整合。血管移植用于修復或取代受损血管，涵盖从心血管外科到週边介入等各个学科，随着人口结构变化导致血管疾病盛行率上升，其重要性也不断提升。生物材料和製造技术的进步正在拓展临床医生的选择，而手术全期护理和诊断影像技术的改进正在重塑手术决策。因此，医疗服务提供者和采购团队必须协调临床绩效需求与营运限制和报销动态。

在此背景下，相关人员需要清晰的、基于临床的产品属性、用例差异化、监管途径和分销考虑。本引言透过阐述推动植入物选择的临床必要性、创造差异化的技术槓桿以及影响应用的商业性机制，为后续分析奠定了基础。透过将临床效用与策略选择连结起来，本节为产品开发、供应链优化和临床应用途径的实际决策奠定了基础。执行摘要的其余部分将从基础理解转向策略考量，探讨结构性变化、关税影响、细分特性、区域动态、竞争定位、建议行动、研究途径以及结论性要点。

临床进展、材料创新和分销现代化如何重塑整个血管假体生态系统的竞争动态

血管假体生态系统正在经历一场变革性的转变，这得益于材料科学的突破、临床通讯协定的不断变化以及医疗服务从集中式转向门诊/门诊的转变。生物製药和合成聚合物的创新使得移植物能够更好地模拟原生血流动力学并降低血栓形成风险，而混合结构和表面修饰则正在扩大其可行适应症的范围。同时，手术路径也在不断发展：微创手术和混合手术室日益普及，改变了手术全期工作流程和器械组装要求。

同时，监管审查和品质标准日益严格，迫使製造商投资于强有力的证据生成和上市后监管。随着相关人员优先考虑多种筹资策略并深化与经销商的伙伴关係关係，供应链的弹性和分销的敏捷性日益受到关注。这些转变，加上采购和临床医生教育的数位化加速，正在推动临床数据和设备使用通讯协定的快速传播。那些将研发重点与不断变化的临床医生工作流程相结合，并投资于严格临床检验的公司，将能够抓住不断扩展的临床用例，并保持长期应用。

评估不断变化的贸易措施和关税动态如何重塑血管移植相关人员的采购决策、供应链弹性和筹资策略

由于关税及相关贸易行动影响筹资策略和成本结构，政策和贸易措施为供应链计算和采购计划引入了新的变数。关税带来的成本压力正促使製造商和医疗保健系统重新评估其供应商布局，考虑近岸外包和回流选项，并重新评估长期合约以降低风险。这些应对措施不仅涉及商业性层面，还会影响临床运营，因为采购计划和库存政策需要进行调整，以确保医疗服务的连续性并维持优先移植类型的可及性。

医疗保健机构越来越多地进行总拥有成本分析，其中涵盖关税、物流变化和潜在延误的影响。同时，製造商也在评估降低关税的措施，例如关税工程、替代路线、关键零件本地化以及与区域契约製造建立战略伙伴关係。最终结果是分销网络重组，并更加重视多层次应急计划。随着相关人员的适应，临床负责人、采购团队和供应链专业人员之间的协作对于平衡成本控制和临床绩效至关重要，并确保病患照护路径不受地缘政治和政策波动的影响。

细緻的细分框架，将产品材料、尺寸、适应症、最终用户环境和分销管道与临床应用和商业策略联繫起来

细分产品类型、尺寸、适应症、最终用户和分销管道等因素，为理解不同的采用模式和临床适用性提供了分析基础。生物移植物（包括同种异体移植物、自体移植物和异质骨移植）具有固有的生物相容性优势，但通常需要特殊的处理和供体来源的考虑。这些材料和处理的差异直接影响临床医生的偏好和库存管理。

将血管直径细分为大、小两类可以进一步完善临床决策，因为尺寸限制和流动动态会改变移植物选择标准和手术技术。从主动脉和脑动脉绕道手术到冠状动脉绕道术、下肢绕道手术、週边动脉绕道手术和肾动脉绕道手术，以适应症为中心的细分强调手术环境对动态和解剖学的要求各不相同，这些要求会影响器械设计和证据要求。门诊手术中心、医院和诊所之间的最终用户差异凸显了手术量、人员配备模式和采购能力方面的差异，这反过来又会影响首选的产品系列。最后，线上和线下的分销管道细分决定了产品到达临床医生和购买者的方式。线下通路持续支援复杂器材的实务训练和物流，而线上管道则促进资讯取得和批量采购。整合这些细分维度使相关人员能够更精准地确定开发、临床证据产生和商业策略，以满足差异化的临床和营运需求。

区域动态和医疗保健系统的细微差别决定了全球主要市场的采购偏好、临床采用途径和分销策略

区域动态正在显着影响整个血管移植领域的临床实践模式、监管格局和供应链架构。在美洲，医疗保健系统将先进的临床基础设施与复杂的报销生态系统相结合，推动了对可靠、长期证据和高性能设备的需求，而大型独立经销商的存在则影响着通路策略和库存实践。在欧洲、中东和非洲，各国医疗保健系统各不相同，需要采取适应性的监管策略和弹性价格设定方法。在亚太地区，新兴市场对成本敏感的采购和都市区快速扩张的临床能力的双重动态为高端和注重价值的产品供应创造了机会。

在全部区域，医生培训途径、手术量以及住院和门诊治疗之间的平衡差异决定了特定植入物类型和技术的采用曲线。与製造地的接近性、区域贸易协定和物流基础设施会影响前置作业时间和库存管理。因此，寻求地理扩张的公司必须根据区域特点客製化其临床参与、监管申报和分销经销伙伴，同时保持一致的品质和证据标准。与当地临床领导者和营运合作伙伴的策略协调对于在不同地区的医疗保健系统中持续采用至关重要。

决定血管移植领域领导地位的关键竞争定位因素，重点在于临床证据、製造能力、策略伙伴关係和商业化模式

血管移植领域的竞争优势取决于临床证据、材料创新、製造可靠性、合规性和管道实力的综合考量。拥有完善製造和上市后监管能力的成熟製造商会利用其过往业绩与大型医院系统和学术中心合作，并通常会将产品系列与培训和临床支持项目相结合，以提升市场偏好。新兴企业和新兴企业则力求透过新型生物材料、表面工程方法和针对性适应症来实现差异化，在特定临床场景中展现其临床优势和易用性。

器械开发商与契约製造以及特种涂层供应商之间的伙伴关係日益普遍，旨在加快临床推广速度并控制资本强度。分销策略多种多样，从大力支持的医院内直销，到透过第三方分销商和电商平台定期补货的混合模式。此外，与临床研究网络和註册平台建立策略联盟，使公司能够产生高品质的真实世界证据，以支持处方和临床医生的采用。最终，能够有效协调研发重点、可扩展生产和差异化商业性模式的公司，最有能力应对报销压力和临床医生的期望，同时保护其长期收益来源。

製造商和医疗保健领导者的策略重点是加强血管移植临床证据、提高供应弹性并确保及时商业化

产业领导者必须在临床、营运和商业层面采取协调一致的行动，以实现长期价值。优先对目标适应症进行严格的临床检验，可以增强报销论点和临床医生的信心，尤其是在证据生成与註册登记和上市后监测相结合，以证明其真实世界疗效的情况下。同时，投资材料科学项目，无论是生物支架、混合结构或表面改质技术，都可以透过通畅性和降低併发症发生率来创造有意义的差异化。

在开发方面，实现製造地多元化并制定紧急采购计划可以降低关税和物流风险。与区域製造商合作还可以加快市场进入速度并缩短前置作业时间。商业性，认识到门诊手术中心与医院和诊所之间的差异，并根据他们的需求量身订做打入市场策略，可以提高采用率。对于复杂的手术，强化教育和实践培训至关重要；而对于大批量生产，精简的采购和可重复的物流支援规模化。最后，利用数位管道与临床医生互动，并利用线上分销进行常规补货，可以补充传统的销售模式。透过实施这些综合建议，组织可以提高韧性，增进临床医生的信任，并使其产品与不断发展的医疗服务规范保持一致。

简要描述用于综合临床、商业和供应链见解的资讯来源、相关人员咨询和分析方法

本研究综合基于对同行评审临床文献、监管和专利现状、公开临床登记册以及与临床医生、供应链负责人和商业专家的相关人员访谈的系统回顾。主要定性资讯是透过结构化咨询获得的，旨在检验临床偏好、设备操作注意事项和采购动态。二级资讯来源提供了有关材料科学趋势、设备核准和程序指南的背景信息，从而能够跨证据流进行三角测量。

分析方法包括：根据不同适应症和直径的临床需求，比较评估器械属性，评估分销管道的有效性，并进行情境分析，以考虑关税导致的供应链调整的影响。我们使用多个独立资讯来源来支持索赔，并注意区分既定的临床共识和新兴假设。自始至终，我们专注于可操作的见解，而非原始的数据集列表，确保研究结果与产品策略、临床参与和采购计划直接相关。在适当的情况下，我们会指出研究的局限性以及需要进一步收集原始数据的领域，指南后续研究和证据生成。

策略整合强调临床检验、材料创新和供应弹性的整合，作为血管移植技术永续应用的基础

这些同步发展创造了一个复杂的环境，其中临床表现、营运弹性和监管协调各自发挥关键作用。相关人员的成功需要整合策略，将严格的证据产生、製造适应性和客製化的商业性执行相结合。

展望未来，最具可持续性的优势将属于那些能够快速将科学进步转化为检验的临床效益、维护灵活且冗余的供应链，并为临床医生提供有针对性的教育和营运支援的组织。如此一来，相关人员就能确保新移植技术的前景得以实现，成为改善病患预后、实现永续临床应用的途径。将技术创新与实际应用结合，是抓住新机会并保障医疗连续性的关键。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

• 内皮化生物工程小直径血管移植物在冠状动脉应用的进展
• 可吸收聚合物复合移植物在儿科血管重建术的应用日益增多
• 肝素涂层膨体聚四氟乙烯移植物在糖尿病患者保肢手术的应用日益增多
• 3D列印患者专用血管移植的出现，可优化动脉瘤修復中的血流动力学性能
• 增加对整合干细胞接种的组织工程移植技术的投资，以提高长期通畅率
• 报销政策和价值导向护理模式的演变对新兴市场血管移植应用的影响

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第八章血管假体市场（依产品类型）

• 生物血管移植
  • 同种异体移植
  • 自体移植
  • 异种移植
• 合成血管移植物
  • 聚酯纤维
  • 聚四氟乙烯
  • 聚氨酯

第九章 人造血管市场（依血管直径）

• 大的
• 小的

第 10 章血管移植市场（按适应症）

• 主髂动脉绕道手术
• 脑动脉绕道手术
• 冠状动脉绕道术
• 下肢搭桥手术
• 週边动脉绕道手术
• 肾臟动脉绕道手术

第 11 章血管移植市场（依最终用户）

• 门诊手术中心
• 医院和诊所

第十二章血管移植市场（依通路）

• 离线
• 在线的

第十三章 人工血管市场：依地区

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十四章血管假体市场（依类别）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十五章 血管假体市场（依国家）

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十六章竞争格局

• 2024年市占率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • Abbott Laboratories
  • Affluent Medical
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • BIOVIC Sdn. Bhd.
  • Boston Scientific Corporation
  • Cardinal Health Inc.
  • Cook Medical, Inc.
  • Corcym Srl
  • CryoLife, Inc.
  • Endologix Inc.
  • Getinge AB
  • Heart Medical Europe BV
  • Japan Lifeline Co., Ltd.
  • Lemaitre Vascular, Inc.
  • Medtronic PLC
  • Merit Medical Systems, Inc.
  • Perouse Medical SAS by Vygon SAS
  • Rua Life Sciences PLC
  • Shanghai Suokang Medical Implants Co. Ltd.
  • Terumo Corporation
  • Vascular Graft Solutions Ltd.
  • VUP Medical
  • WL Gore & Associates, Inc.
  • Xeltis BV

The Vascular Graft Market is projected to grow by USD 4.13 billion at a CAGR of 7.58% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 2.30 billion
Estimated Year [2025]	USD 2.47 billion
Forecast Year [2032]	USD 4.13 billion
CAGR (%)	7.58%

A concise professional framing of the clinical, technological, and commercial imperatives shaping the next era of vascular graft utilization and strategy

The vascular graft landscape is at a pivotal inflection point driven by converging clinical demand, material innovations, and evolving care delivery models. Vascular grafts, which restore or replace compromised blood vessels, intersect disciplines ranging from cardiovascular surgery to peripheral vascular interventions, and their relevance continues to expand as demographic shifts increase the prevalence of vascular disease. Advances in biomaterials and manufacturing have broadened options for clinicians, while improvements in perioperative care and imaging are reshaping procedural decision-making. Consequently, healthcare providers and procurement teams must reconcile clinical performance needs with operational constraints and reimbursement dynamics.

Against this backdrop, stakeholders require a clear, clinically grounded synthesis of product attributes, use-case differentiation, regulatory pathways, and distribution considerations. This introduction frames the subsequent analysis by establishing the clinical imperatives that drive graft selection, the technological levers that create differentiation, and the commercial mechanisms that influence adoption. By linking clinical utility to strategic choices, the section sets the stage for pragmatic decision-making across product development, supply chain optimization, and clinical adoption pathways. Transitioning from foundational understanding to strategic insight, the remainder of the executive summary examines structural changes, tariff implications, segmentation idiosyncrasies, regional dynamics, competitive positioning, recommended actions, research approach, and concluding imperatives.

How clinical practice evolution, materials innovation, and distribution modernization are restructuring competitive dynamics across the vascular graft ecosystem

The vascular graft ecosystem is experiencing transformative shifts driven by material science breakthroughs, shifting clinical protocols, and a reorientation of care delivery away from centralized hospital settings toward outpatient and ambulatory modalities. Innovations in biologics and synthetic polymers are enabling grafts that better mimic native hemodynamics and reduce thrombogenicity, while hybrid constructs and surface modifications are expanding the range of viable indications. At the same time, procedural pathways are evolving: minimally invasive approaches and hybrid operating suites are becoming more prevalent, altering the perioperative workflow and device compatibility requirements.

Concurrently, regulatory scrutiny and quality standards have intensified, prompting manufacturers to invest in robust evidence generation and post-market surveillance. Supply chain resilience and distribution agility have come into sharper focus, with stakeholders prioritizing multiple sourcing strategies and deeper distributor partnerships. These shifts are compounded by an accelerated digital adoption in procurement and clinician education, which supports faster dissemination of clinical data and device use protocols. Taken together, these dynamics create both disruption and opportunity; companies that align R&D priorities with changing clinician workflows and invest in rigorous clinical validation will be positioned to capture expanding clinical use cases and sustain longer-term adoption.

Assessing how evolving trade measures and tariff dynamics are reshaping sourcing decisions, supply chain resiliency, and procurement strategies for vascular graft stakeholders

Policy and trade instruments have introduced a new variable into supply chain calculus and procurement planning, as tariffs and related trade measures influence sourcing strategies and cost structures. Tariff-driven cost pressures have prompted manufacturers and health systems to reassess supplier footprints, consider nearshoring or reshoring options, and revisit long-term contracts to mitigate exposure. These responses are not solely commercial; they also affect clinical operations, as procurement timelines and inventory policies are adjusted to ensure continuity of care and to preserve access to preferred graft types.

Healthcare organizations are increasingly conducting total-cost-of-ownership analyses that incorporate tariff impacts, logistics volatility, and potential delays. In parallel, manufacturers are evaluating tariff mitigation approaches such as tariff engineering, alternative routing, localization of key components, and strategic partnerships with regional contract manufacturers. The net effect is a realignment of distribution networks and a heightened emphasis on multi-tiered contingency planning. As stakeholders adapt, collaboration between clinical leaders, procurement teams, and supply chain experts becomes essential to balance cost containment with clinical performance imperatives and to ensure that patient care pathways remain uninterrupted despite geopolitical and policy fluctuations.

A nuanced segmentation framework linking product materials, sizing, indications, end-user environments, and distribution channels to clinical adoption and commercial strategy

Segmentation provides the analytical scaffolding to understand differential adoption patterns and clinical fit across product categories, sizes, indications, end users, and distribution channels. When viewed through the lens of product type, distinctions between Biological Vascular Grafts and Synthetic Vascular Grafts become salient: biological options encompassing allografts, autografts, and xenografts bring inherent biocompatibility advantages but often require specialized handling and donor-sourcing considerations, whereas synthetic offerings such as polyester, polytetrafluoroethylene, and polyurethane deliver manufacturing consistency and scalable supply chains but must address thrombogenicity and long-term patency concerns. These material and handling differences directly influence clinician preference and inventory management.

Blood vessel diameter segmentation into large and small categories further refines clinical decision-making because sizing constraints and flow dynamics alter graft selection criteria and surgical technique. Indication-focused segmentation underscores that procedural contexts-ranging from aortoiliac bypass surgery and cerebral artery bypass surgery to coronary artery bypass surgery, lower extremity bypass, peripheral artery bypass, and renal artery bypass-impose unique hemodynamic and anatomic demands that affect device design and evidence requirements. End-user distinctions between ambulatory surgical centers and hospitals and clinics highlight divergent procedural volumes, staffing models, and procurement capabilities, which in turn influence preferred product portfolios. Finally, distribution channel segmentation across offline and online pathways shapes how products reach clinicians and purchasers; offline channels continue to support hands-on training and logistics for complex devices, while online channels accelerate information access and volume-based procurement. By integrating these segmentation dimensions, stakeholders can more precisely target development, clinical evidence generation, and commercial strategies to meet differentiated clinical and operational needs.

Regional dynamics and health system nuances that determine procurement preferences, clinical adoption pathways, and distribution strategies across major global markets

Regional dynamics exert a profound influence on clinical practice patterns, regulatory expectations, and supply chain architectures across the vascular graft landscape. In the Americas, health systems exhibit a mix of advanced clinical infrastructure and complex reimbursement ecosystems that drive demands for robust long-term evidence and high-performance devices, while the presence of large independent distributors affects channel strategies and inventory practices. In Europe, Middle East & Africa, heterogeneity across national healthcare systems requires adaptable regulatory strategies and flexible pricing approaches, with some markets emphasizing portability and cost-effectiveness and others prioritizing innovation and premium-performance solutions. The Asia-Pacific region presents a dual dynamic of rapidly expanding clinical capacity in urban centers alongside cost-sensitive procurement in developing markets, creating opportunities for both premium and value-focused product offerings.

Across these regions, differences in physician training pathways, procedural volumes, and hospital versus ambulatory care balance shape adoption curves for specific graft types and technologies. Supply chain implications also vary: proximity to manufacturing hubs, regional trade agreements, and logistics infrastructure affect lead times and inventory management. Consequently, companies pursuing geographic expansion must tailor their clinical engagement, regulatory submissions, and distribution partnerships to regional idiosyncrasies while maintaining consistent quality and evidence standards. Strategic regional alignment, informed by local clinical champions and operational partners, will be critical to unlocking sustained adoption across disparate healthcare systems.

Competitive positioning essentials emphasizing clinical evidence, manufacturing strength, strategic partnerships, and commercialization models that influence leadership in the vascular graft sector

Competitive positioning in the vascular graft domain rests on a combination of clinical evidence, material innovation, manufacturing reliability, regulatory compliance, and channel strength. Established manufacturers with integrated manufacturing and post-market surveillance capabilities leverage their track record to engage large hospital systems and academic centers, often coupling product portfolios with training and clinical support programs to drive preference. Emerging players and startups are differentiating through novel biomaterials, surface-engineering approaches, and targeted indications, seeking to demonstrate clinical superiority or differentiated ease of use in focused clinical scenarios.

Partnerships between device developers and contract manufacturers or specialty coating suppliers are increasingly common as companies accelerate time-to-clinic while controlling capital intensity. Distribution strategies range from deep direct-sales relationships in high-touch hospital environments to hybrid models that employ third-party distributors and e-commerce platforms for routine replenishment. In addition, strategic alliances with clinical research networks and registry platforms enable firms to generate high-quality real-world evidence that supports formulary inclusion and clinician adoption. Ultimately, companies that effectively align R&D priorities with scalable manufacturing and a differentiated commercial approach will be better positioned to navigate reimbursement pressures and clinician expectations while protecting long-term revenue streams.

Actionable strategic priorities for manufacturers and healthcare leaders to strengthen clinical evidence, supply resilience, and tailored commercialization for vascular grafts

Industry leaders must pursue a coordinated set of actions that address clinical, operational, and commercial dimensions to capture long-term value. Prioritizing rigorous clinical validation for targeted indications will strengthen reimbursement discussions and clinician confidence, especially when evidence generation is coupled with registries and post-market surveillance that demonstrate real-world performance. Simultaneously, investing in material science initiatives-whether in biologic scaffolds, hybrid constructs, or surface-modification technologies-can create meaningful differentiation by improving patency and reducing complication rates.

Operationally, diversifying manufacturing footprints and developing contingency sourcing plans will mitigate tariff and logistics risks, while partnerships with regional manufacturers can accelerate market entry and lower lead times. Commercially, tailored go-to-market strategies that recognize differences between ambulatory surgical centers and hospitals and clinics will improve uptake; high-touch education and hands-on training are critical in complex procedures, whereas streamlined procurement and repeatable logistics support scale in high-volume contexts. Finally, embracing digital channels for clinician engagement and leveraging online distribution for routine replenishment can complement traditional sales models. By implementing these integrated recommendations, organizations can enhance resilience, foster clinician trust, and align product offerings with evolving care delivery norms.

A concise description of the evidence sources, stakeholder consultations, and analytical approaches used to synthesize clinical, commercial, and supply chain insights

This research synthesis is grounded in a systematic review of peer-reviewed clinical literature, regulatory documentation, patent landscapes, publicly available clinical registries, and stakeholder interviews with clinicians, supply chain leaders, and commercial experts. Primary qualitative inputs were obtained through structured consultations to validate clinical preferences, device handling considerations, and procurement dynamics. Secondary sources provided context on material science trends, device approvals, and procedural guidelines, enabling triangulation of insights across evidence streams.

Analytical approaches included comparative evaluation of device attributes against clinical requirements for different indications and diameters, assessment of distribution channel efficacy, and scenario analysis to examine the implications of tariff-induced supply chain adjustments. Care was taken to corroborate assertions with multiple independent sources and to distinguish established clinical consensus from emerging hypotheses. Throughout, emphasis was placed on actionable insight rather than raw enumeration of datasets, ensuring that findings are directly relevant to product strategy, clinical engagement, and procurement planning. Where appropriate, limitations and areas requiring further primary data collection are noted to guide follow-up research and evidence generation efforts.

A strategic synthesis highlighting the convergence of clinical validation, material innovation, and supply resilience as the foundation for sustained adoption of vascular graft technologies

In sum, the vascular graft landscape is maturing along multiple dimensions: clinical evidence expectations are rising, material and manufacturing innovations are expanding therapeutic possibilities, and supply chain and distribution strategies are being recalibrated in response to policy and logistical factors. These concurrent developments create a complex environment in which clinical performance, operational resilience, and regulatory alignment each play decisive roles. For stakeholders, success will require integrated strategies that marry rigorous evidence generation with manufacturing adaptability and customized commercial execution.

Moving forward, the most durable advantage will accrue to organizations that can rapidly translate scientific advances into validated clinical benefits, maintain flexible and redundant supply networks, and engage clinicians with targeted educational and operational support. By doing so, stakeholders can ensure that the promise of new graft technologies is realized in improved patient outcomes and sustainable clinical adoption pathways. The concluding call to action is clear: align innovation with pragmatic implementation to capture emerging opportunities while safeguarding continuity of care.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Advancements in bioengineered small-diameter vascular grafts with endothelialization for coronary applications
• 5.2. Increasing adoption of resorbable polymer composite grafts in pediatric vascular reconstruction procedures
• 5.3. Growing utilization of heparin-coated expanded polytetrafluoroethylene grafts in diabetic limb salvage surgeries
• 5.4. Emergence of 3D-printed patient-specific vascular grafts to optimize hemodynamic performance in aneurysm repair
• 5.5. Rising investments in tissue-engineered graft technologies integrating stem cell seeding for improved long-term patency rates
• 5.6. Impact of evolving reimbursement policies and value-based care models on vascular graft adoption in emerging markets

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Vascular Graft Market, by Product Type

• 8.1. Biological Vascular Grafts
  • 8.1.1. Allografts
  • 8.1.2. Autografts
  • 8.1.3. Xenografts
• 8.2. Synthetic Vascular Grafts
  • 8.2.1. Polyester
  • 8.2.2. Polytetrafluoroethylene
  • 8.2.3. Polyurethane

9. Vascular Graft Market, by Blood Vessel Diameter

• 9.1. Large
• 9.2. Small

10. Vascular Graft Market, by Indication

• 10.1. Aortoiliac Bypass Surgery
• 10.2. Cerebral Artery Bypass Surgery
• 10.3. Coronary Artery Bypass Surgery
• 10.4. Lower Extremity Bypass Surgery
• 10.5. Peripheral Artery Bypass Surgery
• 10.6. Renal Artery Bypass Surgery

11. Vascular Graft Market, by End User

• 11.1. Ambulatory Surgical Centers
• 11.2. Hospitals & Clinics

12. Vascular Graft Market, by Distribution Channel

• 12.1. Offline
• 12.2. Online

13. Vascular Graft Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Vascular Graft Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Vascular Graft Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. Abbott Laboratories
  • 16.3.2. Affluent Medical
  • 16.3.3. B. Braun Melsungen AG
  • 16.3.4. Becton, Dickinson and Company
  • 16.3.5. BIOVIC Sdn. Bhd.
  • 16.3.6. Boston Scientific Corporation
  • 16.3.7. Cardinal Health Inc.
  • 16.3.8. Cook Medical, Inc.
  • 16.3.9. Corcym S.r.l.
  • 16.3.10. CryoLife, Inc.
  • 16.3.11. Endologix Inc.
  • 16.3.12. Getinge AB
  • 16.3.13. Heart Medical Europe B.V.
  • 16.3.14. Japan Lifeline Co., Ltd.
  • 16.3.15. Lemaitre Vascular, Inc.
  • 16.3.16. Medtronic PLC
  • 16.3.17. Merit Medical Systems, Inc.
  • 16.3.18. Perouse Medical SAS by Vygon SAS
  • 16.3.19. Rua Life Sciences PLC
  • 16.3.20. Shanghai Suokang Medical Implants Co. Ltd.
  • 16.3.21. Terumo Corporation
  • 16.3.22. Vascular Graft Solutions Ltd.
  • 16.3.23. VUP Medical
  • 16.3.24. W. L. Gore & Associates, Inc.
  • 16.3.25. Xeltis B.V.

LIST OF FIGURES

• FIGURE 1. GLOBAL VASCULAR GRAFT MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL VASCULAR GRAFT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL VASCULAR GRAFT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL VASCULAR GRAFT MARKET SIZE, BY BLOOD VESSEL DIAMETER, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL VASCULAR GRAFT MARKET SIZE, BY BLOOD VESSEL DIAMETER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL VASCULAR GRAFT MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL VASCULAR GRAFT MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL VASCULAR GRAFT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL VASCULAR GRAFT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL VASCULAR GRAFT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL VASCULAR GRAFT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL VASCULAR GRAFT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. AMERICAS VASCULAR GRAFT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. NORTH AMERICA VASCULAR GRAFT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. LATIN AMERICA VASCULAR GRAFT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA VASCULAR GRAFT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. EUROPE VASCULAR GRAFT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. MIDDLE EAST VASCULAR GRAFT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. AFRICA VASCULAR GRAFT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC VASCULAR GRAFT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GLOBAL VASCULAR GRAFT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASEAN VASCULAR GRAFT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GCC VASCULAR GRAFT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. EUROPEAN UNION VASCULAR GRAFT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. BRICS VASCULAR GRAFT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. G7 VASCULAR GRAFT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. NATO VASCULAR GRAFT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. GLOBAL VASCULAR GRAFT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. VASCULAR GRAFT MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 30. VASCULAR GRAFT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. VASCULAR GRAFT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL VASCULAR GRAFT MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL VASCULAR GRAFT MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL VASCULAR GRAFT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL VASCULAR GRAFT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL VASCULAR GRAFT MARKET SIZE, BY ALLOGRAFTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL VASCULAR GRAFT MARKET SIZE, BY ALLOGRAFTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL VASCULAR GRAFT MARKET SIZE, BY ALLOGRAFTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL VASCULAR GRAFT MARKET SIZE, BY ALLOGRAFTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL VASCULAR GRAFT MARKET SIZE, BY ALLOGRAFTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL VASCULAR GRAFT MARKET SIZE, BY ALLOGRAFTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL VASCULAR GRAFT MARKET SIZE, BY AUTOGRAFTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL VASCULAR GRAFT MARKET SIZE, BY AUTOGRAFTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL VASCULAR GRAFT MARKET SIZE, BY AUTOGRAFTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL VASCULAR GRAFT MARKET SIZE, BY AUTOGRAFTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL VASCULAR GRAFT MARKET SIZE, BY AUTOGRAFTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL VASCULAR GRAFT MARKET SIZE, BY AUTOGRAFTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL VASCULAR GRAFT MARKET SIZE, BY XENOGRAFTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL VASCULAR GRAFT MARKET SIZE, BY XENOGRAFTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL VASCULAR GRAFT MARKET SIZE, BY XENOGRAFTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL VASCULAR GRAFT MARKET SIZE, BY XENOGRAFTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL VASCULAR GRAFT MARKET SIZE, BY XENOGRAFTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL VASCULAR GRAFT MARKET SIZE, BY XENOGRAFTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL VASCULAR GRAFT MARKET SIZE, BY POLYESTER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL VASCULAR GRAFT MARKET SIZE, BY POLYESTER, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL VASCULAR GRAFT MARKET SIZE, BY POLYESTER, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL VASCULAR GRAFT MARKET SIZE, BY POLYESTER, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL VASCULAR GRAFT MARKET SIZE, BY POLYESTER, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL VASCULAR GRAFT MARKET SIZE, BY POLYESTER, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL VASCULAR GRAFT MARKET SIZE, BY POLYTETRAFLUOROETHYLENE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL VASCULAR GRAFT MARKET SIZE, BY POLYTETRAFLUOROETHYLENE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL VASCULAR GRAFT MARKET SIZE, BY POLYTETRAFLUOROETHYLENE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL VASCULAR GRAFT MARKET SIZE, BY POLYTETRAFLUOROETHYLENE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL VASCULAR GRAFT MARKET SIZE, BY POLYTETRAFLUOROETHYLENE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL VASCULAR GRAFT MARKET SIZE, BY POLYTETRAFLUOROETHYLENE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL VASCULAR GRAFT MARKET SIZE, BY POLYURETHANE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL VASCULAR GRAFT MARKET SIZE, BY POLYURETHANE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL VASCULAR GRAFT MARKET SIZE, BY POLYURETHANE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL VASCULAR GRAFT MARKET SIZE, BY POLYURETHANE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL VASCULAR GRAFT MARKET SIZE, BY POLYURETHANE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL VASCULAR GRAFT MARKET SIZE, BY POLYURETHANE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL VASCULAR GRAFT MARKET SIZE, BY BLOOD VESSEL DIAMETER, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL VASCULAR GRAFT MARKET SIZE, BY BLOOD VESSEL DIAMETER, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL VASCULAR GRAFT MARKET SIZE, BY LARGE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL VASCULAR GRAFT MARKET SIZE, BY LARGE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL VASCULAR GRAFT MARKET SIZE, BY LARGE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL VASCULAR GRAFT MARKET SIZE, BY LARGE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL VASCULAR GRAFT MARKET SIZE, BY LARGE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL VASCULAR GRAFT MARKET SIZE, BY LARGE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL VASCULAR GRAFT MARKET SIZE, BY SMALL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL VASCULAR GRAFT MARKET SIZE, BY SMALL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL VASCULAR GRAFT MARKET SIZE, BY SMALL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL VASCULAR GRAFT MARKET SIZE, BY SMALL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL VASCULAR GRAFT MARKET SIZE, BY SMALL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL VASCULAR GRAFT MARKET SIZE, BY SMALL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL VASCULAR GRAFT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL VASCULAR GRAFT MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL VASCULAR GRAFT MARKET SIZE, BY AORTOILIAC BYPASS SURGERY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL VASCULAR GRAFT MARKET SIZE, BY AORTOILIAC BYPASS SURGERY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL VASCULAR GRAFT MARKET SIZE, BY AORTOILIAC BYPASS SURGERY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL VASCULAR GRAFT MARKET SIZE, BY AORTOILIAC BYPASS SURGERY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL VASCULAR GRAFT MARKET SIZE, BY AORTOILIAC BYPASS SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL VASCULAR GRAFT MARKET SIZE, BY AORTOILIAC BYPASS SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL VASCULAR GRAFT MARKET SIZE, BY CEREBRAL ARTERY BYPASS SURGERY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL VASCULAR GRAFT MARKET SIZE, BY CEREBRAL ARTERY BYPASS SURGERY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL VASCULAR GRAFT MARKET SIZE, BY CEREBRAL ARTERY BYPASS SURGERY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL VASCULAR GRAFT MARKET SIZE, BY CEREBRAL ARTERY BYPASS SURGERY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL VASCULAR GRAFT MARKET SIZE, BY CEREBRAL ARTERY BYPASS SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL VASCULAR GRAFT MARKET SIZE, BY CEREBRAL ARTERY BYPASS SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL VASCULAR GRAFT MARKET SIZE, BY CORONARY ARTERY BYPASS SURGERY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL VASCULAR GRAFT MARKET SIZE, BY CORONARY ARTERY BYPASS SURGERY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL VASCULAR GRAFT MARKET SIZE, BY CORONARY ARTERY BYPASS SURGERY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL VASCULAR GRAFT MARKET SIZE, BY CORONARY ARTERY BYPASS SURGERY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL VASCULAR GRAFT MARKET SIZE, BY CORONARY ARTERY BYPASS SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL VASCULAR GRAFT MARKET SIZE, BY CORONARY ARTERY BYPASS SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL VASCULAR GRAFT MARKET SIZE, BY LOWER EXTREMITY BYPASS SURGERY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL VASCULAR GRAFT MARKET SIZE, BY LOWER EXTREMITY BYPASS SURGERY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL VASCULAR GRAFT MARKET SIZE, BY LOWER EXTREMITY BYPASS SURGERY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL VASCULAR GRAFT MARKET SIZE, BY LOWER EXTREMITY BYPASS SURGERY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL VASCULAR GRAFT MARKET SIZE, BY LOWER EXTREMITY BYPASS SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL VASCULAR GRAFT MARKET SIZE, BY LOWER EXTREMITY BYPASS SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL VASCULAR GRAFT MARKET SIZE, BY PERIPHERAL ARTERY BYPASS SURGERY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL VASCULAR GRAFT MARKET SIZE, BY PERIPHERAL ARTERY BYPASS SURGERY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL VASCULAR GRAFT MARKET SIZE, BY PERIPHERAL ARTERY BYPASS SURGERY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL VASCULAR GRAFT MARKET SIZE, BY PERIPHERAL ARTERY BYPASS SURGERY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL VASCULAR GRAFT MARKET SIZE, BY PERIPHERAL ARTERY BYPASS SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL VASCULAR GRAFT MARKET SIZE, BY PERIPHERAL ARTERY BYPASS SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL VASCULAR GRAFT MARKET SIZE, BY RENAL ARTERY BYPASS SURGERY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL VASCULAR GRAFT MARKET SIZE, BY RENAL ARTERY BYPASS SURGERY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL VASCULAR GRAFT MARKET SIZE, BY RENAL ARTERY BYPASS SURGERY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL VASCULAR GRAFT MARKET SIZE, BY RENAL ARTERY BYPASS SURGERY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL VASCULAR GRAFT MARKET SIZE, BY RENAL ARTERY BYPASS SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL VASCULAR GRAFT MARKET SIZE, BY RENAL ARTERY BYPASS SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL VASCULAR GRAFT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL VASCULAR GRAFT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL VASCULAR GRAFT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL VASCULAR GRAFT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL VASCULAR GRAFT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL VASCULAR GRAFT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL VASCULAR GRAFT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL VASCULAR GRAFT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL VASCULAR GRAFT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL VASCULAR GRAFT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL VASCULAR GRAFT MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL VASCULAR GRAFT MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL VASCULAR GRAFT MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL VASCULAR GRAFT MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL VASCULAR GRAFT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL VASCULAR GRAFT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL VASCULAR GRAFT MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL VASCULAR GRAFT MARKET SIZE, BY OFFLINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL VASCULAR GRAFT MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL VASCULAR GRAFT MARKET SIZE, BY OFFLINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL VASCULAR GRAFT MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL VASCULAR GRAFT MARKET SIZE, BY OFFLINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL VASCULAR GRAFT MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL VASCULAR GRAFT MARKET SIZE, BY ONLINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL VASCULAR GRAFT MARKET SIZE, BY ONLINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL VASCULAR GRAFT MARKET SIZE, BY ONLINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL VASCULAR GRAFT MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL VASCULAR GRAFT MARKET SIZE, BY ONLINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL VASCULAR GRAFT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL VASCULAR GRAFT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 141. AMERICAS VASCULAR GRAFT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 142. AMERICAS VASCULAR GRAFT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 143. AMERICAS VASCULAR GRAFT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 144. AMERICAS VASCULAR GRAFT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 145. AMERICAS VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, 2018-2024 (USD MILLION)
• TABLE 146. AMERICAS VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, 2025-2032 (USD MILLION)
• TABLE 147. AMERICAS VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, 2018-2024 (USD MILLION)
• TABLE 148. AMERICAS VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, 2025-2032 (USD MILLION)
• TABLE 149. AMERICAS VASCULAR GRAFT MARKET SIZE, BY BLOOD VESSEL DIAMETER, 2018-2024 (USD MILLION)
• TABLE 150. AMERICAS VASCULAR GRAFT MARKET SIZE, BY BLOOD VESSEL DIAMETER, 2025-2032 (USD MILLION)
• TABLE 151. AMERICAS VASCULAR GRAFT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 152. AMERICAS VASCULAR GRAFT MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 153. AMERICAS VASCULAR GRAFT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 154. AMERICAS VASCULAR GRAFT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 155. AMERICAS VASCULAR GRAFT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 156. AMERICAS VASCULAR GRAFT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 157. NORTH AMERICA VASCULAR GRAFT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 158. NORTH AMERICA VASCULAR GRAFT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 159. NORTH AMERICA VASCULAR GRAFT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 160. NORTH AMERICA VASCULAR GRAFT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 161. NORTH AMERICA VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, 2018-2024 (USD MILLION)
• TABLE 162. NORTH AMERICA VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, 2025-2032 (USD MILLION)
• TABLE 163. NORTH AMERICA VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, 2018-2024 (USD MILLION)
• TABLE 164. NORTH AMERICA VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, 2025-2032 (USD MILLION)
• TABLE 165. NORTH AMERICA VASCULAR GRAFT MARKET SIZE, BY BLOOD VESSEL DIAMETER, 2018-2024 (USD MILLION)
• TABLE 166. NORTH AMERICA VASCULAR GRAFT MARKET SIZE, BY BLOOD VESSEL DIAMETER, 2025-2032 (USD MILLION)
• TABLE 167. NORTH AMERICA VASCULAR GRAFT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 168. NORTH AMERICA VASCULAR GRAFT MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 169. NORTH AMERICA VASCULAR GRAFT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 170. NORTH AMERICA VASCULAR GRAFT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 171. NORTH AMERICA VASCULAR GRAFT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 172. NORTH AMERICA VASCULAR GRAFT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 173. LATIN AMERICA VASCULAR GRAFT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 174. LATIN AMERICA VASCULAR GRAFT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 175. LATIN AMERICA VASCULAR GRAFT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 176. LATIN AMERICA VASCULAR GRAFT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 177. LATIN AMERICA VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, 2018-2024 (USD MILLION)
• TABLE 178. LATIN AMERICA VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, 2025-2032 (USD MILLION)
• TABLE 179. LATIN AMERICA VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, 2018-2024 (USD MILLION)
• TABLE 180. LATIN AMERICA VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, 2025-2032 (USD MILLION)
• TABLE 181. LATIN AMERICA VASCULAR GRAFT MARKET SIZE, BY BLOOD VESSEL DIAMETER, 2018-2024 (USD MILLION)
• TABLE 182. LATIN AMERICA VASCULAR GRAFT MARKET SIZE, BY BLOOD VESSEL DIAMETER, 2025-2032 (USD MILLION)
• TABLE 183. LATIN AMERICA VASCULAR GRAFT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 184. LATIN AMERICA VASCULAR GRAFT MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 185. LATIN AMERICA VASCULAR GRAFT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 186. LATIN AMERICA VASCULAR GRAFT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 187. LATIN AMERICA VASCULAR GRAFT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 188. LATIN AMERICA VASCULAR GRAFT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 189. EUROPE, MIDDLE EAST & AFRICA VASCULAR GRAFT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 190. EUROPE, MIDDLE EAST & AFRICA VASCULAR GRAFT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 191. EUROPE, MIDDLE EAST & AFRICA VASCULAR GRAFT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 192. EUROPE, MIDDLE EAST & AFRICA VASCULAR GRAFT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 193. EUROPE, MIDDLE EAST & AFRICA VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, 2018-2024 (USD MILLION)
• TABLE 194. EUROPE, MIDDLE EAST & AFRICA VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, 2025-2032 (USD MILLION)
• TABLE 195. EUROPE, MIDDLE EAST & AFRICA VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, 2018-2024 (USD MILLION)
• TABLE 196. EUROPE, MIDDLE EAST & AFRICA VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, 2025-2032 (USD MILLION)
• TABLE 197. EUROPE, MIDDLE EAST & AFRICA VASCULAR GRAFT MARKET SIZE, BY BLOOD VESSEL DIAMETER, 2018-2024 (USD MILLION)
• TABLE 198. EUROPE, MIDDLE EAST & AFRICA VASCULAR GRAFT MARKET SIZE, BY BLOOD VESSEL DIAMETER, 2025-2032 (USD MILLION)
• TABLE 199. EUROPE, MIDDLE EAST & AFRICA VASCULAR GRAFT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 200. EUROPE, MIDDLE EAST & AFRICA VASCULAR GRAFT MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 201. EUROPE, MIDDLE EAST & AFRICA VASCULAR GRAFT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 202. EUROPE, MIDDLE EAST & AFRICA VASCULAR GRAFT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 203. EUROPE, MIDDLE EAST & AFRICA VASCULAR GRAFT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 204. EUROPE, MIDDLE EAST & AFRICA VASCULAR GRAFT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 205. EUROPE VASCULAR GRAFT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 206. EUROPE VASCULAR GRAFT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 207. EUROPE VASCULAR GRAFT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 208. EUROPE VASCULAR GRAFT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 209. EUROPE VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, 2018-2024 (USD MILLION)
• TABLE 210. EUROPE VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, 2025-2032 (USD MILLION)
• TABLE 211. EUROPE VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, 2018-2024 (USD MILLION)
• TABLE 212. EUROPE VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, 2025-2032 (USD MILLION)
• TABLE 213. EUROPE VASCULAR GRAFT MARKET SIZE, BY BLOOD VESSEL DIAMETER, 2018-2024 (USD MILLION)
• TABLE 214. EUROPE VASCULAR GRAFT MARKET SIZE, BY BLOOD VESSEL DIAMETER, 2025-2032 (USD MILLION)
• TABLE 215. EUROPE VASCULAR GRAFT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 216. EUROPE VASCULAR GRAFT MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 217. EUROPE VASCULAR GRAFT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 218. EUROPE VASCULAR GRAFT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 219. EUROPE VASCULAR GRAFT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 220. EUROPE VASCULAR GRAFT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 221. MIDDLE EAST VASCULAR GRAFT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 222. MIDDLE EAST VASCULAR GRAFT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 223. MIDDLE EAST VASCULAR GRAFT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 224. MIDDLE EAST VASCULAR GRAFT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 225. MIDDLE EAST VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, 2018-2024 (USD MILLION)
• TABLE 226. MIDDLE EAST VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, 2025-2032 (USD MILLION)
• TABLE 227. MIDDLE EAST VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, 2018-2024 (USD MILLION)
• TABLE 228. MIDDLE EAST VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, 2025-2032 (USD MILLION)
• TABLE 229. MIDDLE EAST VASCULAR GRAFT MARKET SIZE, BY BLOOD VESSEL DIAMETER, 2018-2024 (USD MILLION)
• TABLE 230. MIDDLE EAST VASCULAR GRAFT MARKET SIZE, BY BLOOD VESSEL DIAMETER, 2025-2032 (USD MILLION)
• TABLE 231. MIDDLE EAST VASCULAR GRAFT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 232. MIDDLE EAST VASCULAR GRAFT MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 233. MIDDLE EAST VASCULAR GRAFT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 234. MIDDLE EAST VASCULAR GRAFT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 235. MIDDLE EAST VASCULAR GRAFT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 236. MIDDLE EAST VASCULAR GRAFT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 237. AFRICA VASCULAR GRAFT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 238. AFRICA VASCULAR GRAFT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 239. AFRICA VASCULAR GRAFT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 240. AFRICA VASCULAR GRAFT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 241. AFRICA VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, 2018-2024 (USD MILLION)
• TABLE 242. AFRICA VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, 2025-2032 (USD MILLION)
• TABLE 243. AFRICA VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, 2018-2024 (USD MILLION)
• TABLE 244. AFRICA VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, 2025-2032 (USD MILLION)
• TABLE 245. AFRICA VASCULAR GRAFT MARKET SIZE, BY BLOOD VESSEL DIAMETER, 2018-2024 (USD MILLION)
• TABLE 246. AFRICA VASCULAR GRAFT MARKET SIZE, BY BLOOD VESSEL DIAMETER, 2025-2032 (USD MILLION)
• TABLE 247. AFRICA VASCULAR GRAFT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 248. AFRICA VASCULAR GRAFT MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 249. AFRICA VASCULAR GRAFT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 250. AFRICA VASCULAR GRAFT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 251. AFRICA VASCULAR GRAFT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 252. AFRICA VASCULAR GRAFT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 253. ASIA-PACIFIC VASCULAR GRAFT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 254. ASIA-PACIFIC VASCULAR GRAFT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 255. ASIA-PACIFIC VASCULAR GRAFT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 256. ASIA-PACIFIC VASCULAR GRAFT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 257. ASIA-PACIFIC VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, 2018-2024 (USD MILLION)
• TABLE 258. ASIA-PACIFIC VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, 2025-2032 (USD MILLION)
• TABLE 259. ASIA-PACIFIC VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, 2018-2024 (USD MILLION)
• TABLE 260. ASIA-PACIFIC VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, 2025-2032 (USD MILLION)
• TABLE 261. ASIA-PACIFIC VASCULAR GRAFT MARKET SIZE, BY BLOOD VESSEL DIAMETER, 2018-2024 (USD MILLION)
• TABLE 262. ASIA-PACIFIC VASCULAR GRAFT MARKET SIZE, BY BLOOD VESSEL DIAMETER, 2025-2032 (USD MILLION)
• TABLE 263. ASIA-PACIFIC VASCULAR GRAFT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 264. ASIA-PACIFIC VASCULAR GRAFT MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 265. ASIA-PACIFIC VASCULAR GRAFT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 266. ASIA-PACIFIC VASCULAR GRAFT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 267. ASIA-PACIFIC VASCULAR GRAFT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 268. ASIA-PACIFIC VASCULAR GRAFT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 269. GLOBAL VASCULAR GRAFT MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 270. GLOBAL VASCULAR GRAFT MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 271. ASEAN VASCULAR GRAFT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 272. ASEAN VASCULAR GRAFT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 273. ASEAN VASCULAR GRAFT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 274. ASEAN VASCULAR GRAFT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 275. ASEAN VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, 2018-2024 (USD MILLION)
• TABLE 276. ASEAN VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, 2025-2032 (USD MILLION)
• TABLE 277. ASEAN VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, 2018-2024 (USD MILLION)
• TABLE 278. ASEAN VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, 2025-2032 (USD MILLION)
• TABLE 279. ASEAN VASCULAR GRAFT MARKET SIZE, BY BLOOD VESSEL DIAMETER, 2018-2024 (USD MILLION)
• TABLE 280. ASEAN VASCULAR GRAFT MARKET SIZE, BY BLOOD VESSEL DIAMETER, 2025-2032 (USD MILLION)
• TABLE 281. ASEAN VASCULAR GRAFT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 282. ASEAN VASCULAR GRAFT MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 283. ASEAN VASCULAR GRAFT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 284. ASEAN VASCULAR GRAFT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 285. ASEAN VASCULAR GRAFT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 286. ASEAN VASCULAR GRAFT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 287. GCC VASCULAR GRAFT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 288. GCC VASCULAR GRAFT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 289. GCC VASCULAR GRAFT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 290. GCC VASCULAR GRAFT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 291. GCC VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, 2018-2024 (USD MILLION)
• TABLE 292. GCC VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, 2025-2032 (USD MILLION)
• TABLE 293. GCC VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, 2018-2024 (USD MILLION)
• TABLE 294. GCC VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, 2025-2032 (USD MILLION)
• TABLE 295. GCC VASCULAR GRAFT MARKET SIZE, BY BLOOD VESSEL DIAMETER, 2018-2024 (USD MILLION)
• TABLE 296. GCC VASCULAR GRAFT MARKET SIZE, BY BLOOD VESSEL DIAMETER, 2025-2032 (USD MILLION)
• TABLE 297. GCC VASCULAR GRAFT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 298. GCC VASCULAR GRAFT MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 299. GCC VASCULAR GRAFT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 300. GCC VASCULAR GRAFT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 301. GCC VASCULAR GRAFT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 302. GCC VASCULAR GRAFT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 303. EUROPEAN UNION VASCULAR GRAFT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 304. EUROPEAN UNION VASCULAR GRAFT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 305. EUROPEAN UNION VASCULAR GRAFT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 306. EUROPEAN UNION VASCULAR GRAFT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 307. EUROPEAN UNION VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, 2018-2024 (USD MILLION)
• TABLE 308. EUROPEAN UNION VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, 2025-2032 (USD MILLION)
• TABLE 309. EUROPEAN UNION VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, 2018-2024 (USD MILLION)
• TABLE 310. EUROPEAN UNION VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, 2025-2032 (USD MILLION)
• TABLE 311. EUROPEAN UNION VASCULAR GRAFT MARKET SIZE, BY BLOOD VESSEL DIAMETER, 2018-2024 (USD MILLION)
• TABLE 312. EUROPEAN UNION VASCULAR GRAFT MARKET SIZE, BY BLOOD VESSEL DIAMETER, 2025-2032 (USD MILLION)
• TABLE 313. EUROPEAN UNION VASCULAR GRAFT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 314. EUROPEAN UNION VASCULAR GRAFT MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 315. EUROPEAN UNION VASCULAR GRAFT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 316. EUROPEAN UNION VASCULAR GRAFT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 317. EUROPEAN UNION VASCULAR GRAFT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 318. EUROPEAN UNION VASCULAR GRAFT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 319. BRICS VASCULAR GRAFT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 320. BRICS VASCULAR GRAFT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 321. BRICS VASCULAR GRAFT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 322. BRICS VASCULAR GRAFT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
• TABLE 323. BRICS VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, 2018-2024 (USD MILLION)
• TABLE 324. BRICS VASCULAR GRAFT MARKET SIZE, BY BIOLOGICAL VASCULAR GRAFTS, 2025-2032 (USD MILLION)
• TABLE 325. BRICS VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, 2018-2024 (USD MILLION)
• TABLE 326. BRICS VASCULAR GRAFT MARKET SIZE, BY SYNTHETIC VASCULAR GRAFTS, 2025-2032 (USD MILLION)
• TABLE 327. BRICS VASCULAR GRAFT MARKET SIZE, BY BLOOD VESSEL DIAMETER, 2018-2024 (USD MILLION)
• TABLE 328. BRICS VASCULAR GRAFT MARKET SIZE, BY BLOOD VESSEL DIAMETER, 2025-2032 (USD MILLION)
• TABLE 329. BRICS VASCULAR GRAFT MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 330. BRICS VASCULAR GRAFT MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 331. BRICS VASCULAR GRAFT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 332. BRICS VASCULAR GRAFT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 333. BRICS VASCULAR GRAFT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 334. BRICS VASCULAR GRAFT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 335. G7 VASCULAR GRAFT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 336. G7 VASCULAR GRAFT MARKET SIZE, BY COUNTRY, 2025-20